Ask about this productRelated genes to: DNASE2B Blocking Peptide
- Gene:
- DNASE2B NIH gene
- Name:
- deoxyribonuclease 2 beta
- Previous symbol:
- -
- Synonyms:
- DLAD
- Chromosome:
- 1p31.1-p22.3
- Locus Type:
- gene with protein product
- Date approved:
- 2004-12-02
- Date modifiied:
- 2018-02-13
Related products to: DNASE2B Blocking Peptide
Related articles to: DNASE2B Blocking Peptide
- Dysregulation of N6-methyladenosine (m6A) RNA modification plays a critical role in the development and progression of non-small cell lung cancer (NSCLC). To explore the m6A modification landscape in NSCLC, we utilized direct RNA nanopore sequencing (dRNA-seq) to compare m6A patterns between NSCLC and adjacent normal tissues. Our analysis revealed distinct m6A modification differences, with tumor tissues showing reduced m6A density compared to normal tissues. Aberrantly modified genes, such as and , exhibited hypomethylated m6A modifications and were upregulated in NSCLC tissues. We identified 14,419 differentially methylated m6A sites, with 49.5% hypermethylated and 50.5% hypomethylated. Functional enrichment analysis showed that hypermethylated genes were involved in DNA replication and transcription regulation, while hypomethylated genes were linked to cell migration and MAPK signaling. The expression patterns of m6A regulators, including , , , , , and , were consistent across NSCLC subtypes. Furthermore, correlation with clinical data from the TCGA database revealed that m6A-associated DEGs, such as , , , , , , and , were prognostically significant in NSCLC. This study underscores the pivotal role of m6A modifications in NSCLC and highlights the potential of dRNA-seq for identifying RNA epigenetic changes that may serve as novel therapeutic targets. - Source: PubMed
Publication date: 2025/10/24
Li YifeiJiao PengLi DonghangTian YiLi HexinSun GaoyuanWu XiaonanNie XinLi XuXu SiyuanTang XiaokunZhang LiliWan LiZhang LanxinCai JiahuiTang MinLi Lin - This study sought to explore the role of DNASE2B (deoxyribonuclease II beta), a gene specifically overexpressed in prostate cancer (PCa) whose mechanism in driving disease progression remains unclear. We analyzed DNASE2B expression in the TCGA database and PCa cell lines/tissues using Western blotting, q-PCR, and immunohistochemistry. Biological functions were assessed via cell scratch, Transwell, and subcutaneous tumor assays. Immune microenvironment changes were investigated using TISCH2, GEO datasets, and Timer2.0. M2 macrophage infiltration was validated via Transwell, orthotopic models, Immunohistochemistry and immunofluorescence and flow cytometry. Downstream targets were identified, and the DNASE2B-PSA relationship was verified using q-PCR, Western blotting, and ELISA. In vivo models explored the mechanism of M2 regulation. Results showed that DNASE2B expression was significantly higher in PCa tissues than in adjacent normal tissues. Silencing DNASE2B in PC3 cells markedly inhibited malignant progression of PCa both in vitro and in vivo. DNASE2B expression was strongly positively correlated with M2 macrophage infiltration, and it indirectly promoted M2 macrophage infiltration and accelerated PCa progression by affecting PSA secretion. In summary, high DNASE2B expression in PCa cells enhances M2 macrophage infiltration by increasing PSA secretion, thereby driving malignant progression of PCa. - Source: PubMed
Publication date: 2025/09/25
Dai YulinXu JunkaiZhao YunhuiKe DongdongGao QingChen Qisong - Lung adenocarcinoma (LUAD) has high incidence and mortality rates. Efferocytosis is involved in the progression of various cancers. The current work set out to develop a prognosis signature using efferocytosis-related genes (ERGs) for LUAD. - Source: PubMed
Publication date: 2025/09/05
Dai ZengminJin ShaofengHuang ShanshanLiu BingyangShen XingkaiJin Yuhong - Managing Ductal Carcinoma in Situ (DCIS) remains challenging due to the lack of reliable biomarkers to predict radiotherapy (RT) response, leading to both overtreatment of indolent disease and undertreatment of aggressive cases. - Source: PubMed
Publication date: 2025/07/08
Rizvi NoorMucaki Eliseos JSalmini Emily LZhang MonicaTrebinjac SabinaHahn EzraPaszat LawrenceNofech-Mozes SharonHallett Michael TRakovitch EileenDumeaux Vanessa - Papillary thyroid carcinoma (PTC) is the most common endocrine carcinoma in recent years, necessitating more precise risk stratification to accurately identify low-risk patients. Although preliminary evidence exists, studies on lysosomes in PTC are limited. This study utilized multi-omics data from the TCGA database to comprehensively investigate the genomic and biological characteristics of lysosomes in PTC patients and identify lysosome-associated genes (LAGs) linked to PTC prognosis. We developed a LAG scoring system for risk stratification based on the expression levels of risk coefficients and independent prognostic LAG variables. Clinical value was assessed through immune infiltration analysis, pathological subgroup analysis, immunotherapy response, and drug sensitivity prediction. Single-cell sequencing from the GEO database was used to analyze PTC samples, and bioinformatics findings were validated using western blot, qRT-PCR, colony formation, and Transwell assays. A new LAG scoring system was developed based on five prognostic LAGs, with single-cell sequencing revealing their expression in different cell types. The role of one LAG, DNASE2B, in PTC cell cloning, proliferation, and invasion was further confirmed in vitro. This comprehensive study highlights the complex interactions between lysosomes and PTC biology, offering new insights into the role of lysosomes in PTC and identifying potential targets for intervention. - Source: PubMed
Publication date: 2025/06/10
Zhang JianhuaYue KaiWu YanshengJing ChaoWang Xudong